Cost-effectiveness of insulin aspart and human soluble insulin for treatment of type 2 diabetes
Author(s): XU Zhang-rong, JI Qiu-he, XU Fei, YE Qing, Diabetes Center&Endocrinology Department, 306th Hospital of PLA, Department of Endocrinology and Metabolism, Xijing Hospital, Fourth Military Medical University, School of International Pharmaceutical Business, China Pharmaceutical University, Erasmus University, Institute of Health Policy & Management Rotterdam 3062 PA, Netherlands
Pages: 2174-2179
Year: 2014 Issue: 18
Journal: Chinese Journal of New Drugs
Keyword: type 2 diabetes; insulin aspart; human soluble insulin; cost-effectiveness;
Abstract: Objective:To evaluate the long-term cost-effectiveness of switching from human soluble insulin（HI） to insulin aspart（IAsp） in patients with type 2 diabetes mellitus（T2DM） in a Chinese setting.Methods:IMS CORE Diabetes Model was used to project long-term life expectancy,quality-adjusted life years（QALY） and direct medical costs.Baseline cohort characteristics and treatment effects were based on Asian subgroup in A1 chieve study.Costs were derived from published Chinese data.Projections were made from a societal perspective for 30 years,with costs and life years discounted at 3%annually.Results:Switching to IAsp from HI was projected to increase life expectancy by 0.815 years or 1.451 QALYs per patient,and reduce cost by 196 030 RMB.Switching to IAsp from HI on a basal bolus regimen was projected to increase life expectancy by 0.475 years or0.943 QALYs per patient,and reduce cost by 117 077 RMB.Sensitivity analyses demonstrated robustness of the results.Conclusion:Switching to IAsp from HI for Chinese patients with T2DM（whether on a basal-bolus regimen or not） was associated with not only improvements in life expectancy and QALYs,but also significant reduction in total direct medical costs.Switching to IAsp from HI is a cost-saving treatment strategy for T2 DM patients in a Chinese setting.
Pages: 2174-2179
Year: 2014 Issue: 18
Journal: Chinese Journal of New Drugs
Keyword: type 2 diabetes; insulin aspart; human soluble insulin; cost-effectiveness;
Abstract: Objective:To evaluate the long-term cost-effectiveness of switching from human soluble insulin（HI） to insulin aspart（IAsp） in patients with type 2 diabetes mellitus（T2DM） in a Chinese setting.Methods:IMS CORE Diabetes Model was used to project long-term life expectancy,quality-adjusted life years（QALY） and direct medical costs.Baseline cohort characteristics and treatment effects were based on Asian subgroup in A1 chieve study.Costs were derived from published Chinese data.Projections were made from a societal perspective for 30 years,with costs and life years discounted at 3%annually.Results:Switching to IAsp from HI was projected to increase life expectancy by 0.815 years or 1.451 QALYs per patient,and reduce cost by 196 030 RMB.Switching to IAsp from HI on a basal bolus regimen was projected to increase life expectancy by 0.475 years or0.943 QALYs per patient,and reduce cost by 117 077 RMB.Sensitivity analyses demonstrated robustness of the results.Conclusion:Switching to IAsp from HI for Chinese patients with T2DM（whether on a basal-bolus regimen or not） was associated with not only improvements in life expectancy and QALYs,but also significant reduction in total direct medical costs.Switching to IAsp from HI is a cost-saving treatment strategy for T2 DM patients in a Chinese setting.
Related Articles